Loading data for STOK — first visit, this takes a few seconds.

알림

Stoke Therapeutics Inc. (STOK)

NasdaqGS: STOK · 실시간 가격 · USD

32.14

+0.01 (0.03%)

종가 기준: Aug 18, 2026, 8:00 PM

0.03% (1D)

데이터 없음

매수호가	n/a
시가총액	2.07B
매출 (ttm)	27.59M
순이익 (ttm)	-207.9M
베타	1.23
EPS (ttm)	-3.39
P/E (ttm)	n/a
선행 P/E	-9.2
P/B (ttm)	5.80
P/S (ttm)	75.17
Earnings Date	Nov 3, 2026

매도호가	n/a
거래량	570,966
평균 거래량 (20일)	801,567
시가	31.85
전일 종가	32.13
일중 범위	31.40 - 32.67
52주 범위	18.00 - 40.22
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

STOK 소개

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 19, 2019

직원 수 170

상장 거래소 NasdaqGS

티커 STOK

웹사이트 https://www.stoketherapeutics.com

전체 기업 정보

재무 실적

2025년 Stoke Therapeutics의 매출은 184.42M로, 전년 36.55M 대비 404.5% 증가했습니다. 순이익은 -6.88M로, -92.26% 감소했습니다.

재무제표

어닝 서프라이즈

Stoke Therapeutics가 Aug 3, 2026에 분기 실적을 발표했습니다:

매출 $9.32M 예상치 하회 $0, 및 -32.51% 전년 대비 감소.

EPS -0.93 예상치 하회 -0.15, 및 -132.50% 전년 대비 감소.

다음 실적 발표

Stoke Therapeutics Inc.의 실적 발표 예정일은 Nov 3, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Motley Fool

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Phase III enrollment complete for zorevunersen with zero discontinuation rates.

1주 전 · Simply Wall St.

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?

Stoke Therapeutics (NasdaqGS:STOK) filed a shelf registration for a potential 2,000,000 common share offering reportedly tied to an Employee Stock Ownership Plan. The filing indicates possible future ...

2주 전 · Moby

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Stoke Therapeutics, Inc.'s Q2 2026 earnings call

2주 전 · GuruFocus.com

Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...

Stoke Therapeutics Inc (STOK) reports robust financial runway and rapid Phase 3 enrollment, but key efficacy data remains pending until Q3 2027.

2주 전 · MarketBeat

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completio...

2 페이지 중 1

Stoke Therapeutics Inc. (STOK)